SCHEMBL8320677

SCHEMBL8320677

CC(C)(C)OC(=O)N[C@H]1CCC(=O)C1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSK P43235 2/20 0.50
BTK Q06187 1/20 0.50
GAA P10253 2/20 0.49
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
KDM1A O60341 1/20 0.47
MAOB P27338 1/20 0.47
EPHX2 P34913 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
KMT2A Q03164 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
DRD2 P14416 2/20 0.41
EPHX1 P07099 1/20 0.41
KCNA3 P22001 1/20 0.41
CYP2C9 P11712 1/20 0.39
HSD11B1 P28845 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL720530 1.00 CTSK (0.50) CTSKBTKGAANFKB1NFKB2
SCHEMBL720531 1.00 CTSK (0.50) CTSKBTKGAANFKB1NFKB2
SCHEMBL117269 0.91 BTK (0.51) CTSKBTKGAANFKB1NFKB2
SCHEMBL21597571 0.90 BTK (0.55) CTSKBTKGAANFKB1NFKB2
SCHEMBL10239204 0.90 BTK (0.55) CTSKBTKGAANFKB1NFKB2
SCHEMBL132145 0.90 BTK (0.55) CTSKBTKGAANFKB1NFKB2
SCHEMBL24874466 0.89 BTK (0.54) CTSKBTKGAANFKB1NFKB2
SCHEMBL13735251 0.89 BTK (0.54) CTSKBTKGAANFKB1NFKB2
Bicarbonate SCHEMBL3395208 0.88 BTK (0.53) CTSKBTKGAANFKB1NFKB2
SCHEMBL570801 0.85 GAA (0.54) CTSKBTKGAANFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600698-B2 Kinase inhibitors VIDYA THERAPEUTICS, INC. (US) 2026-04-14 US disclosed
EP-3890828-B1 HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2025-02-19 EP disclosed
EP-4277893-A1 INDOLE DERIVATIVES AS KINASE INHIBITORS GB005, Inc. (US) 2023-11-22 EP disclosed
US-20230174481-A1 KINASE INHIBITORS VIDYA THERAPEUTICS, INC. 2023-06-08 US disclosed
US-20230174481-A1 KINASE INHIBITORS VIDYA THERAPEUTICS, INC. 2023-06-08 US disclosed
US-20230174481-A1 KINASE INHIBITORS VIDYA THERAPEUTICS, INC. 2023-06-08 US disclosed
WO-2023086575-A1 BTK INHIBITORS BIOGEN MA INC. (US) 2023-05-19 WO disclosed
US-20220409593-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS 2022-12-29 US disclosed
EP-4048677-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME Arkuda Therapeutics (US) 2022-08-31 EP disclosed
WO-2022155111-A1 INDOLE DERIVATIVES AS KINASE INHIBITORS GB005, INC. (US) 2022-07-21 WO disclosed
EP-3983387-A1 SULFONYLUREA DERIVATIVES AND USES THEREOF Nodthera Limited (GB) 2022-04-20 EP disclosed
US-20210353610-A1 SMALL MOLECULE MENIN INHIBITORS SERVIER PHARMACEUTICALS LLC 2021-11-18 US disclosed
WO-2021081272-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS (US) 2021-04-29 WO disclosed
US-5925624-A ANTIINFLAMMATORY AGENTS TREATING PATIENTS WITH INFLAMMATORY CONDITIONS SUSCEPTIBLE TO LEUKOCYTE-INDUCED TISSUE DAMAGE GLAXO GROUP LIMITED (GB) 1999-07-20 US disclosed
US-5889178-A N-(2,2-DIPHENYLETHYL)-DERIVATIVES GLAXO GROUP LIMITED (GB) 1999-03-30 US disclosed
EP-0680488-B1 2,6-DIAMINOPURINE DERIVATIVES GLAXO GROUP LTD (GB) 1998-04-08 EP disclosed
EP-0680488-A1 2,6-DIAMINOPURINE DERIVATIVES GLAXO GROUP LIMITED (GB) 1995-11-08 EP disclosed
WO-1994017090-A1 2,6-DIAMINOPURINE DERIVATIVES GLAXO GROUP LIMITED (GB) 1994-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210353610-A1 SMALL MOLECULE MENIN INHIBITORS MEN1, BRCA1, KRAS CTSK 3482/4885BTK 3131/4885GAA 2423/4885
US-12600698-B2 Kinase inhibitors BTK, BMX, GSK3B CTSK 3060/4885BTK 1/4885GAA 1323/4885
US-20230174481-A1 KINASE INHIBITORS BTK, LYN, LCK CTSK 815/4885BTK 1/4885GAA 914/4885
US-20220409593-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME GRN, PSEN1, PSEN2 CTSK 579/4885BTK 4831/4885GAA 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.